NASDAQ:PDLI PDL BioPharma (PDLI) Stock Price, News & Analysis → Thousands of investors use this no cost solution | Do you? (From Insider Financial) (Ad) Free PDLI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.47▼$2.4750-Day Range$2.47▼$2.4752-Week Range$2.09▼$3.86VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get PDL BioPharma alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About PDL BioPharma Stock (NASDAQ:PDLI)PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.Read More Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! PDLI Stock News HeadlinesFebruary 23, 2024 | morningstar.comGT Biopharma Inc GTBPOctober 24, 2023 | thestreet.comHealth Winners & Losers: MaxygenApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.October 18, 2023 | investing.comPDLI Historical DataJune 28, 2023 | finance.yahoo.comABVC - ABVC BioPharma, Inc.June 23, 2023 | finance.yahoo.comRDHL - RedHill Biopharma Ltd.March 12, 2023 | seekingalpha.comLABPJanuary 15, 2023 | msn.comA Persons Deprived of Liberty (PDL) interacts with his pet mouse inside the jailApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.January 4, 2023 | thestreet.comPDL BioPharma Stock To Go Ex-dividend Monday (PDLI)December 14, 2022 | thestreet.comPDL BioPharma Stock To Go Ex-dividend Tomorrow (PDLI)August 6, 2022 | thestreet.comCramer's 'Mad Money' Recap: Politics Is OverratedMay 21, 2022 | forbes.comSteris (STE)See More Headlines Receive PDLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDL BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2020Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:PDLI CUSIP69329Y10 CIK882104 Webwww.pdl.com Phone775-832-8500Fax775-832-8501Employees109Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Dominique P. Monnet (Age 59)CEO, Pres & Director Comp: $1.2MMr. Edward A. Imbrogno CPA (Age 55)VP, CFO & Chief Accounting Officer Comp: $564.14kMr. Christopher L. Stone (Age 56)VP, Gen. Counsel & Sec. Comp: $1.15MMr. Nathan KryszakDeputy Gen. Counsel & Assistant Sec.Key CompetitorsGenocea BiosciencesNASDAQ:GNCAQVectivBioNASDAQ:VECT180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWView All Competitors PDLI Stock Analysis - Frequently Asked Questions How were PDL BioPharma's earnings last quarter? PDL BioPharma, Inc. (NASDAQ:PDLI) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by $0.53. The biotechnology company had revenue of $5.21 million for the quarter. What other stocks do shareholders of PDL BioPharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other PDL BioPharma investors own include AT&T (T), OPKO Health (OPK), Advanced Micro Devices (AMD), Novavax (NVAX), General Electric (GE), Teva Pharmaceutical Industries (TEVA), Bank of America (BAC), Bausch Health Companies (BHC) and Cara Therapeutics (CARA). This page (NASDAQ:PDLI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDL BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
